P latelets may be small, but their behavior in vivo is governed by molecular mechanisms every bit as complex as those in larger cells. New molecules that provide unexpected insights turn up with surprising regularity. One recent example is the connexin family member Cx37 or GJA4. The role of Cx37 in platelets is examined in this issue of Circulation by Vaiyapuri et al, 1 but a related study by Angelillo-Scherrer et al 2 appeared here a year ago, and both will be considered together.
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Cx37 is a member of a family of gap junction proteins that can assemble a comparatively nonselective channel when cells come into close contact with each other. These channels are large enough to allow free passage of soluble molecules such as cAMP, Ca 2ϩ , and IP 3 (inositol 1,4,5-trisphosphate) between cells. They are formed by the interaction of 2 Cx37 hemichannels on the surface of opposing cells. Hemichannels themselves can also pass small molecules, but with different specificities than the complete channel (see Kar et al 3 for a recent review).
The identification of a previously unsuspected molecule in platelets inevitably leads to questions about its role in either platelets or megakaryocytes. Platelets have limited synthetic capability. According to current models, they are formed by carefully orchestrated events in which proteins synthesized by megakaryocytes are transshipped to the tip of a developing proplatelet projection. 4 Presumably anything found in mature platelets is there for a reason. What, then, is the role of Cx37? Based on studies in other cells, it is possible to make some reasoned guesses. However, as will be discussed below, published evidence leaves the answer in platelets somewhat uncertain.
First, consider that a major design goal of platelets is to be able to form a stable hemostatic plug in response to vascular injury while at the same time avoiding either unnecessary platelet activation or excessive platelet accumulation. There are both positive and negative regulators of platelet activation that have a substantial impact. The initial capture of rapidly moving platelets is mediated by the binding of glycoprotein Ib␣ on the platelet surface to the von Willebrand factor that decorates collagen fibrils in the damaged vessel wall. Activation often begins with the collagen receptor glycoprotein VI and the thrombin receptors PAR1 and PAR4 (proteaseactivated receptors 1 and 4; Figure) . It is reinforced by local accumulation of ADP (secreted by platelets and released by damaged cells) and thromboxane A 2 (released by activated platelets). As additional platelets join the growing hemostatic mass, integrin ␣ IIb ␤ 3 on the platelet surface binds to fibrinogen, fibrin, and von Willebrand factor, forming an array of adhesive connections between platelets. ␣ IIb ␤ 3 is present at very high copy number on resting platelets and increases to even higher levels of surface expression when platelets are activated. Events within the platelet trigger the conformational shift that allows ␣ IIb ␤ 3 to bind its ligands and hold platelet aggregates together.
The major pathways that support platelet activation have been mapped, mutated, and targeted by the pharmaceutical and biotech industries, producing drugs that have found widespread clinical use. However, platelet biology does not begin or end with a rapid response to vascular injury. In addition to identifying roles for platelets outside of hemostasis, past studies have shown that the quiescent state of platelets is actively maintained before injury and that events that occur after platelet aggregation help to stabilize the hemostatic plug. Cx37, the focus of this brief commentary, appears to play a role in regulating thrombus growth and stability.
Formation of Platelet-Platelet Junctions
As activated platelets come into ␣ IIb ␤ 3 -mediated contact with each other, other proteins on the surface of adjacent platelets come close enough for long enough to interact in trans ( Figure) . In a recent review, we cited a number of examples of this phenomenon, including the ephrin and semaphorin family members ephrinB1 and sema4D. Like Cx37, ephrinB1 and sema4D entered the platelet literature as surface proteins whose role in hemostasis was unknown. 5 It is now known that by binding to their cognate receptors on adjacent platelets, ephrinB1 and sema4D are able to initiate signaling events that reinforce platelet activation. 6 11 and TLT-1 (TREMlike transcript 1). 12 Interestingly, platelet function has been found to be increased rather than decreased in mice that lack PECAM-1, 13 CEACAM-1, 14 JAM-A, 15 or ESAM, 16 which suggests that this group of molecules normally serves to restrain rather than promote thrombus growth and stability. Despite this lengthy list of junction-associated molecules and the growing evidence for contact-dependent signaling in platelets, it remains unclear whether adjacent platelets form any of the classic junctional structures found in other cell types, such as tight, adherens, or gap junctions. The narrowing distances between activated platelets in a growing hemostatic plug or thrombus brings adjacent platelet membranes close enough to each other that protein-protein interactions are possible. The gaps that remain provide a relatively protected environment in which soluble molecules can accumulate and the entry (or exit) of plasma proteins can be restrained. However, the evidence that platelets form actual junctional structures is limited, even though a number of reports have documented the presence of junction-forming molecules in platelets (Elrod et al, 17 among others). Close contacts between platelets have been documented by a number of investigators using electron microscopy, including most recently Vaiyapuri et al. 1 However, it is not yet clear from those studies that there are actual junctional structures.
Connexin 37
In this context, the identification of Cx37 on platelets is especially intriguing. The evidence that it is expressed by platelets is compelling. The evidence for its role is somewhat contradictory. Both of the groups that have examined Cx37 function in platelets were able to show that small molecules can pass between adjacent platelets in an aggregate, neurobiotin in one case 2 and calcein in the other. 1 Blockade or deletion of the Cx37 channels prevented passage of the tracers.
After that, however, their observations diverge. AngelilloScherrer and her colleagues 2 found that deleting Cx37 in mice reduced the tail bleeding time, shortened the time to occlusive thrombosis, accelerated mortality in a disseminated thrombosis model, and enhanced platelet aggregation in response to suboptimal concentrations of ADP, thrombin, and collagen. A Cx37-blocking peptide mimicked the effects of the knockout by promoting platelet aggregation. The authors proposed that Cx37 forms a channel when platelets are in stable contact that permits passage of a molecule such as cAMP from one platelet to another. Because rising cAMP levels suppress platelet reactivity, transferred cAMP would act as an inhibitor, and preventing transfer would conceivably cause the observed gain of function in the Cx37 knockout. Note, however, that although the transfer of cAMP between cells other than platelets has been demonstrated, cAMP transfer between platelets remains an interesting speculation.
In contrast, Vaiyapuri et al 1 in the current issue of Circulation found a loss of function when they studied platelets from what appears to be the same Cx37 knockout mouse line that was studied by Angelillo-Scherrer et al. The deletion of Cx37 reduced platelet aggregation. It also inhibited fibrino- 
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gen binding and ␣-granule secretion under conditions when platelet-platelet contacts were excluded. Cx37 blockers had comparable inhibitory effects, which were seen both when single platelets were observed by flow cytometry and under conditions when aggregation occurred. Receptor-proximal signaling events seemed to occur normally, but the rise in cytosolic Ca 2ϩ concentration that usually accompanies platelet activation was blunted. These results suggest that the contribution of Cx37 is not limited to settings in which platelets come into stable contact with each other but also occurs when only hemichannels are present.
Thus, although there is agreement that platelets express Cx37, there is no consensus on its role, with one group concluding that Cx37 helps to repress platelet activation, whereas another concludes that it promotes platelet activation. The reasons for these differences are not clear. The inhibitors used by both groups vary in their mechanisms of action and are vulnerable to off-target effects. The Cx37 knockout was not limited to platelets. Effects of the knockout on cells other than platelets may have contributed to the effects observed in vivo but are less obviously relevant in studies performed with isolated platelets. Each report made use of multiple methods and is internally consistent, so the conundrum remains. Therefore, however tempting it may be to assign Cx37 a role in communication between platelets after stable platelet-platelet contacts have formed, it is still premature to do so. The tale of gaps and junctions between platelets is far from complete.
Sources of Funding
This work was supported by grants from the NIH HLBI ( L.F.B.) and American Heart Association (T.J.S.).
Disclosures
None.
